Market Overview

Analysts Come Out Bullish On Radius Health, Shares Rally

Related RDUS
The Journal of Clinical Endocrinology & Metabolism Publishes Radius Health's Phase II Study Of The Investigational Drug Abaloparatide In Postmenopausal Women With Osteoporosis
1 Way To Search For The 'Next Big Thing' In Biotech

Early Wednesday morning, four analyst firms issued notes initiating bullish coverage on Radius Health (NASDAQ: RDUS).

Shares of Radius Health have shot up nearly six percent on the news. The firms respective ratings and price targets are listed below.

  • Canaccord Genuity - Buy, $21
  • Cowen & Company - Outperform, N/A
  • Cantor Fitzgerald - Buy, $20
  • Jefferies - Buy, $17

The average of these price targets is $19.33, which represents 53 percent upside to last check price of $12.62.

Latest Ratings for RDUS

Nov 2014Cantor FitzgeraldMaintainsBuy
Oct 2014Canaccord GenuityMaintainsBuy
Sep 2014Canaccord GenuityMaintainsBuy

View More Analyst Ratings for RDUS
View the Latest Analyst Ratings

Posted-In: Canaccord Genuity Cantor FitzgeraldAnalyst Color Price Target Initiation Hot Analyst Ratings Movers


Related Articles (RDUS)

Around the Web, We're Loving...

Get Benzinga's Newsletters